Form 4: Summit Therapeutics CEO Reports Stock Transaction

Sentiment:

Insider Transaction (Form 4)


Mahkam Zanganeh, Co-Chief Executive Officer, a Director and 10% owner of Summit Therapeutics Inc., reported multiple transactions in common stock on November 16, 2026.

Summary

  • Option exercise/conversion: acquired 500,000 Common Stock at $1.06 ($530,000) on November 16, 2026; holds 531,000 after (Direct).
  • Option exercise/conversion: disposed of 500,000 Stock Option (right to buy) on November 16, 2026; holds 800,000 after (Direct).

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as routine: the reported changes are grants, option exercises, tax withholding or similar administrative transactions, which carry limited directional signal.

Insider Transactions

Mahkam Zanganeh — Director, Officer (Co-Chief Executive Officer), 10% owner

DateTransactionSecuritySharesPriceValueHeld After
2026-11-16Option exercise/conversionCommon Stock500,000$1$530.0K531,000
2026-11-16Option exercise/conversionStock Option (right to buy)500,000——800,000

Key Dates

DateDescription
2026-11-16Option exercise/conversion (500,000 shares)
2026-11-16Option exercise/conversion (500,000 shares)

Keywords

insider transaction, Form 4, SMMT, Summit Therapeutics Inc., neutral, Mahkam Zanganeh

Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.